Sartorius (FRA:SRT3) has been assigned a €200.00 ($232.56) price target by research analysts at Deutsche Bank in a research report issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. Deutsche Bank’s price target would suggest a potential downside of 6.28% from the company’s current price.
Other equities analysts have also issued reports about the stock. Berenberg Bank set a €145.00 ($168.60) price objective on shares of Sartorius and gave the company a “sell” rating in a research report on Monday, October 21st. Nord/LB set a €150.00 ($174.42) price objective on shares of Sartorius and gave the company a “sell” rating in a research report on Friday, October 25th. Warburg Research set a €184.00 ($213.95) price objective on shares of Sartorius and gave the company a “neutral” rating in a research report on Monday, October 21st. UBS Group set a €192.00 ($223.26) target price on shares of Sartorius and gave the company a “neutral” rating in a research note on Monday, December 9th. Finally, JPMorgan Chase & Co. set a €205.00 ($238.37) target price on shares of Sartorius and gave the company a “buy” rating in a research note on Monday, January 6th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of €166.56 ($193.67).
SRT3 stock opened at €213.40 ($248.14) on Tuesday. The firm has a 50 day moving average of €195.31 and a 200-day moving average of €181.85. Sartorius has a 12 month low of €71.00 ($82.56) and a 12 month high of €124.70 ($145.00).
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.